Other Targets

You can also try the following methods, and our professionals will serve you Customized Consultation

Cat. No.	Product Name	Field of Application
DC20593	5Z-7-Oxozeaenol	A potent, selective TAK1 inhibitor with IC50 of 8 nM, displays >33-fold and >62-fold selectivity over MEKK1 and MEKK4 respectively.
DC22578	TPO-Agonist-1	A potent, selective thrombopoietin (TPO) receptor agonist..
DC23548	TLR9 inhibitor 18	A potent, selective TLR9 antagonist with IC50 of 13 nM (human TLR9), displays 75-fold selectivity over TLR7 and no activity against TLR8 (IC50>10 uM).
DC20878	CDK7 and 9 inhibitor 14	A potent, selective transcriptional CDK inhibitor with Ki of 2.3 and 0.38 nM for CDK7 and CDK9, respectively.
DC22786	CB34	A potent, selective translocator protein 18 kDa (TSPO/PBR) agonist with IC50 of 2.59 and 1.03 nM in competing with [3H]-PK11195 for binding to membrane preparations from rat cerebral cortex and ovary, respectively.
DC21220	Larixyl acetate	A potent, selective TRPC6 channel inhibitor with IC50 of 0.1-0.6 uM, 12- and 5-fold selectivity over related TRPC3 and TRPC7.
DC21820	WS-12	A potent, selective TRPM8 agonist with EC50 of 12 uM, a cooling agent.
DC24043	USP8-IN-22e Featured	A potent, selective ubiquitin-specific protease USP8 inhibitor with IC50 of 0.28 uM.
DC24042	USP8-IN-22c	A potent, selective ubiquitin-specific protease USP8 inhibitor with IC50 of 0.56 uM.
DC24041	USP8-IN-22d	A potent, selective ubiquitin-specific protease USP8 inhibitor with IC50 of 0.85 uM.
DC22696	BRL 44408 Featured	A potent, selective α2A-adrenoceptor antagonist with Ki of 1.7 nM, 80-fold selectivity over α2B-adrenergic receptors.
DC22695	BRL 44408 maleate	A potent, selective α2A-adrenoceptor antagonist with Ki of 1.7 nM, 80-fold selectivity over α2B-adrenergic receptors.
DC22694	ARC 239 dihydrochloride	A potent, selective α2B adrenoceptor antagonist with pKd of 8.8, 200-fold selectivity over α2A, and α2D receptors.
DC22536	CFMTI Featured	A potent, selective, allosteric and oral mGluR1 antaognist with IC50 of 2.6 and 2.3 nM for human and rat mGluR1, respectively.
DC22753	NS13001 Featured	A potent, selective, allosteric and orally acitve positive modulator of small-conductance calcium-activated K+ channel KCa2.2 and KCa2.3 with EC50 of 1.6 and 0.14 uM, respectively.
DC21316	ML400	A potent, selective, allosteric LMPTP inhibitor with IC50 of 1.68 uM, displays good selective against other phosphatases.
DC22916	JNJ-10397049	A potent, selective, and bioavailable OX2 receptor antagonist with Kb of 4.5 nM.
DC23971	LY450108	A potent, selective, and centrally active positive allosteric modulator of AMPAR-mediated neurotransmission, which increase ion channel flux in the presence of agonist by suppressing desensitization and/or deactivation of the receptors..
DC24030	LY451395 Featured	A potent, selective, and centrally active positive allosteric modulator of AMPAR-mediated neurotransmission, which increase ion channel flux in the presence of agonist by suppressing desensitization and/or deactivation of the receptors..
DC23963	QL-47	A potent, selective, and irreversible BTK inhibitor with IC50 of 7 nM.
DC21545	PXS-4681A	A potent, selective, and irreversible inhibitor of SSAO/VAP-1 (AOC3) with Ki of 37 nM, IC50 of <10 nM.
DC21254	LY-517717	A potent, selective, and orally bioavailable factor Xa (FXa) inhibitor for prevention and treatment of thromboembolic diseases..
DC21487	PF-05190457 Featured	A potent, selective, and orally bioavailable ghrelin receptor (GHSR) inverse agonist with binding pKi of 8.36.
DC23541	IRAK4-IN-16	A potent, selective, and orally bioavailable inhibitor of interleukin-1 receptor-associate kinase-4 (IRAK4) with IC50 of 2.8 nM, 217- and 892-fold selectivity over IRAK-1 and TAK1, respectively.
DC23949	CX-6258 hydrochloride hydrate	A potent, selective, and orally efficacious pan-Pim inhibitor with IC50 of 5/25/16 nM for Pim1/2/3, respectively.
DC23036	BI-69A11	A potent, selective, ATP competitive AKT inhibitor with IC50 of 2.3 uM for Akt1.
DC22651	PF-4950834	A potent, selective, ATP-competitive and orally acitve Rho kinase inhibitor with IC50 of 33.1 and 8.5 nM for ROCK1 and ROCK2, respectively.
DC23867	PF-00337210	A potent, selective, ATP-competitive and orally bioavailable inhibitor of VEGFR-2 with Ki of 0.7 and 8.8 nM for unactivated and fully phosphorylated VEGFR-2, respectively.
DC23930	Bay 65-1942	A potent, selective, ATP-competitive inhibitor of IKKβ kinase with Ki of 2 nM.
DC22500	Bay 65-1942 hydrochloride	A potent, selective, ATP-competitive inhibitor of IKKβ kinase with Ki of 2 nM.

Other Targets

Customized Consultation X

Your information is safe with us. * Required Fields.